ClinicalTrials.gg
CompletedNCT00422734Updated Jun 10, 2009Results posted

Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life

A Phase 3 interventional study of tadalafil and Placebo in Impotence, sponsored by Eli Lilly and Company. Completed at 19 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-10.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
342
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.

Enrollment
20th of 56
342 · median 199
Started
2006
the only one that year
Phase 3
19 of 57
2 open now
Registered
9th of 57
by date
Lead sponsor
26 of 57
Eli Lilly and Company

Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 20th largest by enrollment of the 56 interventional ones that give a count, is the only one that started in 2006, is one of 19 in phase 3, and was the 9th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing tadalafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

To determine if tadalafil 5 mg daily compared to placebo when given for 12 weeks improves getting and maintaining an erection in men with erectile dysfunction and if there are improvements in the sexual quality of life of the man and his female study partner

03

Conditions studied

  • Impotence

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male

  • History of erectile dysfunction (ED) for at least 3 months duration
  • Anticipate having the same female partner willing to participate throughout the study
  • At least 18 years of age at Visit 1 and agree to make at least 4 sexual attempts during the early phase of the study
  • Adequate partner sexual function as determined by a Female Sexual Function Index
  • Willing to record responses to efficacy questionnaires, sexual quality of life questionnaires and other instruments used in the study

Exclusion criteria

Exclusion Criteria:

  • May not participate in the study if you have taken tadalafil previously.
  • History of cardiac conditions including angina requiring treatment with nitrates, heart disease of coronary conditions including myocardial infarction, bypass surgery, angioplasty or stent placement for specified time before starting the study.
  • Have sexual partner not willing to complete the scales.
  • Use of nitrates.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
342 participants (actual)

Study arms

  • Placebo comparator
    1

    Placebo

    Drug: Placebo

  • Active comparator
    2

    5 mg tadalafil

    Drug: tadalafil

Interventions

  • 5 mg tadalafil tablet taken by mouth once a day for 12 weeks

    Also known as: LY450190, Cialis, IC351

  • DrugPlacebo

    placebo tablet taken by mouth once a day for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF)- Erectile Function Domain Score (Sum of IIEF Questions 1-5 and 15)

    Measures erectile function over the past 4 weeks on Questions 1-5 and 15 (6 questions) of the International Index of Erecile Function (IIEF) questionnaire. Scores range from 0 (low/no erectile function) to 5 (high erectile function), thus the 6 questions of the IIEF-EF domain range from 0 to 30.

    Time frame: Baseline and 12 weeks

  2. Improvement in the Sexual Quality of Life in the Subject and His Study Partner as Measured by the Sexual Quality of Life (SQoL) Domain of the Sexual Life Quality Questionnaire (SLQQ)

    The original item scores (-4 to 4 range) were converted to 0 to 8 scale score by adding 4 to each recorded responses. Each transformed score was multiplied by 12.5 for a total range of 0 to 100. Higher scores are indicative of a higher sexual quality of life.

    Time frame: Baseline and 12 weeks

  3. Change From Baseline to Endpoint in the Percent of "Yes" Responses to Sexual Encounter Profile (SEP) Diary Questions 2 (SEP2) and 3 (SEP3).

    The baseline and endpoint score for each SEP question 2 (Insert penis into vagina) and 3 (Successful intercourse) are the subject's percentage of "yes" responses to those questions during the run-in period and postbaseline period, respectively.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change From Baseline to Week 12 Endpoint in the International Index of Erectile Function - Intercourse Satisfaction Domain - Subject Response

    Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.

    Time frame: Baseline and 12 weeks

  2. Change From Baseline to 12 Week Endpoint in Overall Satisfaction Domain of the International Index of Erectile Function (IIEF-OS) - Subject Response

    Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.

    Time frame: Baseline and 12 weeks

  3. Sexual Life Quality Questionnaire (SLQQ) Treatment Satisfaction Domain

    The 6 SLQQ-treatment satisfaction questions were answered by subject and partner at Visit 4/Final Visit. Original item scores (1 to 6 range) were converted to 0 to 5 scale by subtracting 1 to each recorded responses. Each transformed score was multiplied by 20. Total range of scores: 0 (low satisfaction) to 100 (high satisfaction).

    Time frame: 12 weeks

  4. Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Sexual Encounter Profile (SEP) Questions 4 and 5 - Subject Response

    The baseline and endpoint score for each SEP question 4 (Satisfied with hardness) and 5 (Satisfied overall) are the subject's percentage of "yes" responses to those questions during the run-in period and postbaseline period, respectively.

    Time frame: Baseline and 12 weeks

  5. Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Partner-Sexual Encounter Profile (SEP) Question 3 - Partner Response

    The baseline and endpoint score for partner SEP question 3 (Satisfied overall) are the partner's percentage of "yes" responses to the question during the run-in period and postbaseline period, respectively.

    Time frame: Baseline and 12 weeks

  6. Change From Baseline to 12 Week Endpoint in the Satisfaction Domain of the Female Sexual Function Index (FSFI) - Partner Response

    The FSFI Satisfaction Domain (items 14-16) measures satisfaction with emotional closeness, sexual relationship, and overall sexual life. Each question is scored on a 0/1 to 5 scale and domain score is calculated by multiplying the total points by 0.4, for a total score range of 0.8 to 6, with higher scores indicating greater satisfaction.

    Time frame: Baseline and 12 weeks

  7. Percent of Subjects With "Yes" Responses to Global Assessment Questionnaire (GAQ) - Subject Response

    Percent of subjects with "Yes" responses to Question 1 (Improvement in Erections) and Question 2 (Improvement in the Ability to Engage in Sexual Activity)

    Time frame: 12 weeks

  8. Percent of Partners With "Yes" Responses to Global Assessment Questionnaire (GAQ) - Partner Response

    Percent of Partners with "Yes" responses to Question 1 (Improvement in Erections) and Question 2 (Improvement in the Ability to Engage in Sexual Activity)

    Time frame: 12 weeks

  9. Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Partner-Sexual Encounter Profile (SEP) Questions 1 and 2 - Partner Response

    The baseline and endpoint score for each SEP question 1 (Achieve some erection) and 2 (Insert penis into vagina) are the partner's percentage of "yes" responses to those questions during the run-in period and postbaseline period, respectively.

    Time frame: Baseline and 12 weeks

  10. Change From Baseline to 12 Week Endpoint in the Self-Esteem and Relationship (SEAR) Questionnaire

    Measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). Overall score is transformed onto a 0 (least favorable) to 100 (most favorable) scale. Overall score was calculated from two domains and subscales scores.

    Time frame: Baseline and 12 weeks

  11. Change From Baseline to 12 Week Endpoint in the Self-Esteem and Relationship (SEAR) Questionnaire - Confidence Domain Subscales

    Measures improvement in confidence (items 9-14). Confidence domain consists of two subscales (Self-Esteem, items 9-12; Overall Relationship, items 13 and 14). Each domain score, subscale score, and overall score are transformed onto a 0 (least favorable) to 100 (most favorable) scale.

    Time frame: Baseline and 12 weeks

07

Results

Posted Jun 2, 2009

Participant flow

Participant flow — Overall Study
MilestonePlaceboTadalafil
Started78264
Completed64243
Not completed1421
Withdrew: Physician decision11
Withdrew: Protocol violation16
Withdrew: Withdrawal by subject128
Withdrew: Adverse event03
Withdrew: Partner decision03

Outcome measures

PrimaryChange From Baseline to Endpoint in the International Index of Erectile Function (IIEF)- Erectile Function Domain Score (Sum of IIEF Questions 1-5 and 15)

Measures erectile function over the past 4 weeks on Questions 1-5 and 15 (6 questions) of the International Index of Erecile Function (IIEF) questionnaire. Scores range from 0 (low/no erectile function) to 5 (high erectile function), thus the 6 questions of the IIEF-EF domain range from 0 to 30.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF)- Erectile Function Domain Score (Sum of IIEF Questions 1-5 and 15)
units on a scalePlaceboTadalafil
Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF)- Erectile Function Domain Score (Sum of IIEF Questions 1-5 and 15)0.49 ± 0.7818.03 ± 0.449
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (Hypotheses were tested in a sequential fashion using a gatekeeping strategy and adjusted for multiplicity. Statistical significance at 0.05 level was required for this variable)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
PrimaryImprovement in the Sexual Quality of Life in the Subject and His Study Partner as Measured by the Sexual Quality of Life (SQoL) Domain of the Sexual Life Quality Questionnaire (SLQQ)

The original item scores (-4 to 4 range) were converted to 0 to 8 scale score by adding 4 to each recorded responses. Each transformed score was multiplied by 12.5 for a total range of 0 to 100. Higher scores are indicative of a higher sexual quality of life.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · units on a scale
Improvement in the Sexual Quality of Life in the Subject and His Study Partner as Measured by the Sexual Quality of Life (SQoL) Domain of the Sexual Life Quality Questionnaire (SLQQ)
units on a scalePlaceboTadalafil
SQoL - Subject (change from baseline)12.59 ± 2.86639.37 ± 1.651
SQoL-Partner (change from baseline) (n=70, n=238)7.93 ± 2.86132.87 ± 1.638
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (P-value for Subject. Hypotheses were tested in a sequential fashion using a gatekeeping strategy and adjusted for multiplicity. To adjust for multiplicity, statistical significance at 0.025 level was required for this variable.)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (P-value for Partner. Hypotheses were tested in a sequential fashion using a gatekeeping strategy and adjusted for multiplicity. To adjust for multiplicity, statistical significance at 0.025 level was required for this variable.)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
SecondaryChange From Baseline to Week 12 Endpoint in the International Index of Erectile Function - Intercourse Satisfaction Domain - Subject Response

Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 Endpoint in the International Index of Erectile Function - Intercourse Satisfaction Domain - Subject Response
units on a scalePlaceboTadalafil
Change From Baseline to Week 12 Endpoint in the International Index of Erectile Function - Intercourse Satisfaction Domain - Subject Response0.09 ± 0.3562.74 ± 0.205
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = <0.001Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
SecondaryChange From Baseline to 12 Week Endpoint in Overall Satisfaction Domain of the International Index of Erectile Function (IIEF-OS) - Subject Response

Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 12 Week Endpoint in Overall Satisfaction Domain of the International Index of Erectile Function (IIEF-OS) - Subject Response
units on a scalePlaceboTadalafil
Change From Baseline to 12 Week Endpoint in Overall Satisfaction Domain of the International Index of Erectile Function (IIEF-OS) - Subject Response0.44 ± 0.2572.57 ± 0.148
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = <0.001Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
SecondarySexual Life Quality Questionnaire (SLQQ) Treatment Satisfaction Domain

The 6 SLQQ-treatment satisfaction questions were answered by subject and partner at Visit 4/Final Visit. Original item scores (1 to 6 range) were converted to 0 to 5 scale by subtracting 1 to each recorded responses. Each transformed score was multiplied by 20. Total range of scores: 0 (low satisfaction) to 100 (high satisfaction).

Time frame:
12 weeks
Reported as:
Least squares mean · units on a scale
Sexual Life Quality Questionnaire (SLQQ) Treatment Satisfaction Domain
units on a scalePlaceboTadalafil
SLQQ - Subject (n=72, n=244)51.58 ± 2.24675.04 ± 1.293
SLQQ - Partner (n=70, n=238)55.25 ± 2.11573.42 ± 1.214
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (p-value is for subject scores)ANCOVA included:treatment, baseline value of IIEF EF Domain, pooled site. Baseline-value-by-treatment interaction included if interaction at p\<0.10
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (p-value is for partner scores)ANCOVA included:treatment, baseline value of IIEF EF Domain, pooled site. Baseline-value-by-treatment interaction included if interaction at p\<0.10
PrimaryChange From Baseline to Endpoint in the Percent of "Yes" Responses to Sexual Encounter Profile (SEP) Diary Questions 2 (SEP2) and 3 (SEP3).

The baseline and endpoint score for each SEP question 2 (Insert penis into vagina) and 3 (Successful intercourse) are the subject's percentage of "yes" responses to those questions during the run-in period and postbaseline period, respectively.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · percent
Change From Baseline to Endpoint in the Percent of "Yes" Responses to Sexual Encounter Profile (SEP) Diary Questions 2 (SEP2) and 3 (SEP3).
percentPlaceboTadalafil
Question 2 change from baseline in percent "yes"2.19 ± 2.83328.80 ± 1.644
Question 3 change from baseline in percent "yes"10.80 ± 3.76746.46 ± 2.185
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (P-value for SEP Question 2. Hypotheses were tested in a sequential fashion using a gatekeeping strategy and adjusted for multiplicity. Statistical significance at 0.05 level was required for this variable.)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (P-value for SEP Question 3. Hypotheses were tested in a sequential fashion using a gatekeeping strategy and adjusted for multiplicity. Statistical significance at 0.05 level was required for this variable.)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
SecondaryChange From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Sexual Encounter Profile (SEP) Questions 4 and 5 - Subject Response

The baseline and endpoint score for each SEP question 4 (Satisfied with hardness) and 5 (Satisfied overall) are the subject's percentage of "yes" responses to those questions during the run-in period and postbaseline period, respectively.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · percent
Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Sexual Encounter Profile (SEP) Questions 4 and 5 - Subject Response
percentPlaceboTadalafil
Question 4 change from baseline in percent "Yes"12.08 ± 3.93650.05 ± 2.283
Question 5 change from baseline in percent "Yes"11.47 ± 3.95148.78 ± 2.292
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (p-value for SEP Question 4)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (p-value for SEP Question 5)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
SecondaryChange From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Partner-Sexual Encounter Profile (SEP) Question 3 - Partner Response

The baseline and endpoint score for partner SEP question 3 (Satisfied overall) are the partner's percentage of "yes" responses to the question during the run-in period and postbaseline period, respectively.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · percent
Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Partner-Sexual Encounter Profile (SEP) Question 3 - Partner Response
percentPlaceboTadalafil
Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Partner-Sexual Encounter Profile (SEP) Question 3 - Partner Response10.21 ± 3.59543.16 ± 2.072
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = <0.001Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
SecondaryChange From Baseline to 12 Week Endpoint in the Satisfaction Domain of the Female Sexual Function Index (FSFI) - Partner Response

The FSFI Satisfaction Domain (items 14-16) measures satisfaction with emotional closeness, sexual relationship, and overall sexual life. Each question is scored on a 0/1 to 5 scale and domain score is calculated by multiplying the total points by 0.4, for a total score range of 0.8 to 6, with higher scores indicating greater satisfaction.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 12 Week Endpoint in the Satisfaction Domain of the Female Sexual Function Index (FSFI) - Partner Response
units on a scalePlaceboTadalafil
Change From Baseline to 12 Week Endpoint in the Satisfaction Domain of the Female Sexual Function Index (FSFI) - Partner Response-0.40 ± 0.1300.32 ± 0.075
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = <0.001Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
SecondaryPercent of Subjects With "Yes" Responses to Global Assessment Questionnaire (GAQ) - Subject Response

Percent of subjects with "Yes" responses to Question 1 (Improvement in Erections) and Question 2 (Improvement in the Ability to Engage in Sexual Activity)

Time frame:
12 weeks
Reported as:
Number · percentage of subjects answering Yes
Percent of Subjects With "Yes" Responses to Global Assessment Questionnaire (GAQ) - Subject Response
percentage of subjects answering YesPlaceboTadalafil
GAQ Question 12681
GAQ Question 22279
Statistical analysis
  • Placebo vs Tadalafil · Regression, Logistic · p = <0.001 (P-value is for GAQ Question 1)Model included:treatment, baseline value of IIEF EF Domain, pooled site. Baseline-value-by-treatment interaction included if interaction at p\<0.10
  • Placebo vs Tadalafil · Regression, Logistic · p = <0.001 (P-value is for GAQ Question 2)Model included:treatment, baseline value of IIEF EF Domain, pooled site. Baseline-value-by-treatment interaction included if interaction at p\<0.10
SecondaryPercent of Partners With "Yes" Responses to Global Assessment Questionnaire (GAQ) - Partner Response

Percent of Partners with "Yes" responses to Question 1 (Improvement in Erections) and Question 2 (Improvement in the Ability to Engage in Sexual Activity)

Time frame:
12 weeks
Reported as:
Number · percentage of partners answering Yes
Percent of Partners With "Yes" Responses to Global Assessment Questionnaire (GAQ) - Partner Response
percentage of partners answering YesPlaceboTadalafil
GAQ Question 13079
GAQ Question 22476
Statistical analysis
  • Placebo vs Tadalafil · Regression, Logistic · p = <0.001 (P-value is for GAQ Question 1)Model included:treatment, baseline value of IIEF EF Domain, pooled site. Baseline-value-by-treatment interaction included if interaction at p\<0.10
  • Placebo vs Tadalafil · Regression, Logistic · p = <0.001 (P-value is for GAQ Question 2)Model included:treatment, baseline value of IIEF EF Domain, pooled site. Baseline-value-by-treatment interaction included if interaction at p\<0.10
SecondaryChange From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Partner-Sexual Encounter Profile (SEP) Questions 1 and 2 - Partner Response

The baseline and endpoint score for each SEP question 1 (Achieve some erection) and 2 (Insert penis into vagina) are the partner's percentage of "yes" responses to those questions during the run-in period and postbaseline period, respectively.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · percent
Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Partner-Sexual Encounter Profile (SEP) Questions 1 and 2 - Partner Response
percentPlaceboTadalafil
Question 1 change from baseline in percent "Yes"1.25 ± 2.22418.34 ± 1.270
Question 2 change from baseline in percent "Yes"6.97 ± 2.89630.69 ± 1.662
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (P-value is for SEP Question 1)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (P-value is for SEP Question 2)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
SecondaryChange From Baseline to 12 Week Endpoint in the Self-Esteem and Relationship (SEAR) Questionnaire

Measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). Overall score is transformed onto a 0 (least favorable) to 100 (most favorable) scale. Overall score was calculated from two domains and subscales scores.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 12 Week Endpoint in the Self-Esteem and Relationship (SEAR) Questionnaire
units on a scalePlaceboTadalafil
Total Score change from baseline3.07 ± 2.61630.44 ± 1.506
Sexual Relationship change from baseline4.61 ± 2.90334.28 ± 1.673
Confidence change from baseline0.91 ± 2.56725.35 ± 1.475
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (P-value is for SEAR Total Score)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (P-value is for SEAR Sexual Relationship)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (P-value is for SEAR Confidence)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
SecondaryChange From Baseline to 12 Week Endpoint in the Self-Esteem and Relationship (SEAR) Questionnaire - Confidence Domain Subscales

Measures improvement in confidence (items 9-14). Confidence domain consists of two subscales (Self-Esteem, items 9-12; Overall Relationship, items 13 and 14). Each domain score, subscale score, and overall score are transformed onto a 0 (least favorable) to 100 (most favorable) scale.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 12 Week Endpoint in the Self-Esteem and Relationship (SEAR) Questionnaire - Confidence Domain Subscales
units on a scalePlaceboTadalafil
Self-Esteem change from baseline3.26 ± 2.74329.56 ± 1.579
Overall Relationship change from baseline-4.04 ± 2.79216.97 ± 1.603
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (P-value is for SEAR Self-Esteem)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.
  • Placebo vs Tadalafil · ANCOVA · p = <0.001 (P-value is for SEAR Overall Relationship)Change from baseline ANCOVA model: treatment group, baseline value, pooled site. Baseline-by-treatment interaction included if interaction at p\<0.10.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo———
Tadalafil———
Most frequent serious events
Most frequent serious events
EventPlaceboTadalafil
PancreatitisGastrointestinal disorders1/780/264
HypersensitivityImmune system disorders0/781/264
GastroenteritisInfections and infestations0/781/264
Cerebrovascular accidentNervous system disorders0/781/264
Most frequent other events
Showing 10 of 76
Most frequent other events
EventPlaceboTadalafil
HeadacheNervous system disorders3/7822/264
DyspepsiaGastrointestinal disorders0/7812/264
GastroenteritisInfections and infestations3/782/264
Nasal congestionRespiratory, thoracic and mediastinal disorders0/787/264
FatigueGeneral disorders2/780/264
DiarrhoeaGastrointestinal disorders1/785/264
Gastrooesophageal reflux diseaseGastrointestinal disorders0/785/264
Back painMusculoskeletal and connective tissue disorders1/785/264
Pain in extremityMusculoskeletal and connective tissue disorders0/785/264
MyalgiaMusculoskeletal and connective tissue disorders0/784/264

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboTadalafilTotal
Mean53.82 ± 10.7254.42 ± 10.0454.29 ± 10.18
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTadalafilTotal
Female000
Male78264342
Region of Enrollment
Region of Enrollment(participants)PlaceboTadalafilTotal
France114152
United States29107136
Mexico196382
Austria81725
Germany113647
Erectile Dysfunction History - Duration
Erectile Dysfunction History - Duration(participants)PlaceboTadalafilTotal
>= 1 year73240313
>= 3 months and < 6 months189
>= 6 months and < 1 year41620
Erectile Dysfunction History - Etiology
Erectile Dysfunction History - Etiology(participants)PlaceboTadalafilTotal
Mixed34114148
Organic2991120
Psychogenic123042
Unknown32932
International Index of Erectile Function (IIEF) - Erectile Dysfunction Severity
International Index of Erectile Function (IIEF) - Erectile Dysfunction Severity(participants)PlaceboTadalafilTotal
Mild (17-30)35123158.0
Moderate (11-16)227193.0
Severe (1-10)206383.0
Missing178.0
Race/Ethnicity
Race/Ethnicity(participants)PlaceboTadalafilTotal
African066
Caucasian57188245
Hispanic216990
Native American011
International Index of Erectile Function (IIEF) - Erectile Function Domain
International Index of Erectile Function (IIEF) - Erectile Function Domain(units on a scale)PlaceboTadalafilTotal
Mean15.27 ± 6.4915.73 ± 6.1315.62 ± 6.21
08

Study locations

19 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Huntsville, Alabama 35801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Little Rock, Arkansas 72211, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newport Beach, California 92660, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stuart, Florida 34996, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampa, Florida 33607, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Des Moines, Iowa 50309, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cleveland, Ohio 44106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Knoxville, Tennessee 37920, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Virginia Beach, Virginia 23454, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salzburg, 5020, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lille, 59000, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marseille, 13009, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rennes, 35 700, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Augsburg, D-86150, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 13465, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, D-20354, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leverkusen, 51375, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Joya, 14000, Mexico
09

References and documents

Publications

  • Porst H, Gacci M, Buttner H, Henneges C, Boess F. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. Eur Urol. 2014 Feb;65(2):455-64. doi: 10.1016/j.eururo.2013.09.037. Epub 2013 Oct 2. PubMed 24119319 ↗
  • Shabsigh R, Seftel AD, Kim ED, Ni X, Burns PR. Efficacy and safety of once-daily tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline. J Sex Med. 2013 Mar;10(3):844-56. doi: 10.1111/j.1743-6109.2012.02898.x. Epub 2012 Oct 4. PubMed 23035781 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2007
First posted
Jan 17, 2007
Start
Nov 2006
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Jun 2, 2009
Last update
Jun 10, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00422734
Collaborators
ICOS Corporation
First posted
Jan 17, 2007
Start date
Nov 2006
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Jun 2, 2009
Last update
Jun 10, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion